Jazz Pharma, MD Anderson Collaborate To Evaluate Zanidatamab In HER2-Expressing Cancers
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Jazz Pharmaceuticals plc (JAZZ) and The University of Texas MD Anderson Cancer Center announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancer
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1358880761-82e600bfa20f4c2a8c48dc39cebeb0b0.jpg "<div>Accountant vs. Controller: What's the Difference?</div>")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-td-bank-cd-rates-march-2023-7482856-1d7d5a82f0ca496b9b1d63739cd7f567.jpg "TD Bank CD Rates: November 2024")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-fidelity-cd-rates-may-2023-7496602-4e8485ac0a5349a5bb10885241012896.jpg "Fidelity CD Rates: November 2024")